Drugs that have transformed the treatment of obesity may have another, unexpected role to play: helping people struggling with addiction.
Medicines such as semaglutide, best known through brands including Wegovy and Ozempic, were developed primarily to treat diabetes and obesity. Yet researchers have increasingly become interested in reports that some people taking these drugs experience something beyond a reduced appetite for food.
Their desire for alcohol, cigarettes and potentially other addictive substances appears, in some cases, to diminish as well.
It has opened an intriguing new avenue of medical research. Could drugs designed to quiet hunger also quiet addiction?
Turning Down the Volume on Craving
Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists. They imitate a naturally occurring hormone involved in appetite, blood-sugar regulation and feelings of fullness.
But GLP-1 receptors are also present in areas of the brain associated with motivation and reward.
That has led scientists to investigate whether these medicines could influence the neurological machinery involved in craving.
The idea is particularly interesting because addiction is considerably more complicated than simply lacking willpower. Alcohol, nicotine and other drugs can alter the brain’s reward systems, reinforcing behaviour and creating powerful patterns of craving and dependence.
If GLP-1 medicines can influence some of those pathways, their usefulness could extend considerably beyond weight management.
Evidence Emerging Around Alcohol
Alcohol has produced some of the most interesting findings.
A randomized clinical trial of semaglutide involving people with alcohol-use disorder found reductions in laboratory alcohol consumption and alcohol craving.
Intriguingly, participants who smoked also reported reductions in the number of cigarettes they consumed.
Further research published in 2026 has strengthened scientific interest in the relationship between GLP-1 drugs and alcohol consumption.
Researchers are consequently investigating whether medicines such as semaglutide could eventually become another weapon available to doctors treating alcohol-use disorder.
That would represent a remarkable second act for a class of drugs already reshaping obesity medicine.
Could They Help Smokers Too?
Nicotine dependence is another area attracting researchers’ attention.
Scientists are investigating whether GLP-1 medicines could reduce cigarette consumption or make quitting easier. The possibility makes biological sense if these medicines genuinely influence the brain’s reward and craving circuits.
Research has also explored associations between GLP-1 medicines and the use of substances including opioids and cannabis.
But this is precisely where caution becomes important.
The evidence does not currently justify describing semaglutide or similar medicines as cures for alcoholism, smoking or drug addiction.
Some studies are observational, meaning researchers can identify associations without necessarily proving that the medicine itself caused the change.
Much larger and longer clinical trials will be required.
Not a Miracle Cure
There is another danger surrounding the extraordinary popularity of weight-loss medicines: hype can travel considerably faster than medical science.
Addiction is complex. Genetics, mental health, social circumstances, trauma, environment and the pharmacological effects of individual substances can all play a role.
A weekly injection is unlikely to erase all of those factors.
Established treatments for alcohol, nicotine and drug dependence therefore remain essential, including medical treatment, psychological therapies, smoking-cessation programmes and peer-support services.
Anyone already receiving treatment for addiction should not abandon it because of reports concerning weight-loss drugs.
Nor should people attempt to obtain GLP-1 medicines specifically to treat addiction without appropriate medical supervision.
An Accidental Medical Discovery?
Medicine has a long history of drugs finding important uses their inventors never anticipated.
GLP-1 medicines may eventually join that list.
What began as a way of controlling blood sugar developed into one of the most important advances in obesity treatment for decades. Now researchers are asking whether the same biological mechanism might help explain something even more fundamental: why human beings crave things.
If scientists can understand how these medicines alter reward, desire and compulsive behaviour, the implications could extend far beyond weight loss.
For millions of people struggling with alcohol, nicotine and other addictions, that possibility deserves serious investigation.
But the distinction between hope and proof matters.
GLP-1 medicines have not yet become a magic injection against addiction. What scientists have discovered instead is arguably more interesting: a new path of research into the biology of craving itself.
And sometimes in medicine, an unexpected path leads somewhere extraordinary.
